Newsletter | April 16, 2024

04.16.24 -- 8 Key Takeaways Of The Proposed FDA Modernization Act 3.0

SPONSOR

FEATURED EDITORIAL

8 Key Takeaways Of The Proposed FDA Modernization Act 3.0

By Rajendran (Raj) Arunagiri

On Feb. 6, 2024, new legislation was introduced in the House of Representatives: the FDA Modernization Act 3.0. It aims to reduce and replace the use of animals in nonclinical research, improve predictivity of nonclinical testing, and potentially reduce drug development times. This article shares an overview. Note that the proposed legislation would still need to go through its course of passing the House and Senate and being signed by the president before becoming a law.

INDUSTRY INSIGHTS

Identify And Mitigate Absorption Risks With PBPK Modeling

Webinar | Lonza

PBPK models combined with custom and off-the shelf in vitro tools and solubility enhancement expertise can reduce the need for drug product reformulation or repeated preclinical or clinical studies.

Key Stages In mRNA-Based Therapeutic Development

White Paper | Precision NanoSystems

Review how planning a product development strategy early on with a technology partner who has deep expertise and technical knowledge of genomic medicines can address uncertainties from the outset.

A Century Of Cell Culture And The Rise Of Organ-Chips

Article | Emulate

Despite its advantages in researching biological processes, 2D cell culture suffers from its artificial nature. Learn about 3D cell culture and how it is advancing in vitro studies.

Particle Investigation: Going One Step Further Than Just The Identification

Webinar | Lonza

Discover examples of visible particle identification and the root cause investigation, along with a discussion of the performance of additional troubleshooting using advanced and innovative technologies.